Results 181 to 190 of about 5,266 (226)

Reversible Thrombocytopenia Associated with Eptifibatide

The Annals of Pharmacotherapy, 2002
OBJECTIVE: To report a patient who experienced severe, reversible thrombocytopenia after receiving eptifibatide for acute coronary syndrome. CASE SUMMARY: A 61-year-old white man with a past medical history of coronary artery disease, peripheral vascular disease, insulin-dependent diabetes, hypertension, and dyslipidemia was treated with eptifibatide ...
Rebecca F Edwards, Monty Yoder
openaire   +3 more sources

Eptifibatide-induced thrombocytopenia and thrombosis

Journal of Thrombosis and Thrombolysis, 2006
Glycoprotein (GP) IIb/IIIa inhibitors have been shown to reduce morbidity and mortality in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). With their widespread use, there is a growing body of literature describing adverse outcomes, including severe thrombocytopenia.
Mike Militello, Ross Downey, Deepu Nair, Slava Epelman, Arman T. Askari   +4 more
openaire   +2 more sources

Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide

Journal of Cardiovascular Pharmacology, 2021
: Patients with percutaneous coronary interventions undergoing procedures often require interruptions in their dual antiplatelet therapy. Periprocedural bridging is considered for patients at high thrombotic risk using intravenous cangrelor, a reversible
Allison N. Yun, A. Toyoda, Edmond J. Solomon, R. Roberts, Christine S. Ji   +4 more
semanticscholar   +1 more source

Eptifibatide-Associated Acute, Profound Thrombocytopenia

Annals of Pharmacotherapy, 2005
OBJECTIVE: To describe 3 cases of eptifibatide-associated acute, profound thrombocytopenia. CASE SUMMARIES: A 40-year-old black female received eptifibatide 180-μg/kg double bolus followed by a continuous infusion of 2 μg/kg/min for percutaneous coronary intervention (PCI).
James C. Coons, Tucker Freedy, Michael F. Hagerty, Robert A Barcelona   +3 more
openaire   +2 more sources

Evaluación económica de eptifibatide

Revista Española de Cardiología, 2001
Introduccion y objetivos El objetivo de este estudio es realizar una evaluacion economica para Espana del ensayo PURSUIT, un estudio multicentrico y aleatorio sobre el tratamiento de la angina inestable o el infarto sin onda Q con eptifibatide frente a placebo, asi como medir el coste de cada ano de vida ganado en los pacientes tratados con dicho ...
Francisco Antón Botella, Fernando Jesús Antoñanzas Villar   +1 more
openaire   +2 more sources

Development of eptifibatide

American Heart Journal, 1999
The primary cause of acute coronary syndromes is the development of a thrombus, a pathologic manifestation of platelet aggregation that occurs as part of the normal process of hemostasis. The discovery that the final common step in platelet aggregation, through the binding of fibrinogen to the activated platelet integrin glycoprotein (GP) IIb/IIIa, has
openaire   +2 more sources

Abstract WP185: Intraarterial Eptifibatide as an Adjunct to Refractory Multi-Pass Mechanical Thrombectomy

Stroke
Eptifibatide is a glycoprotein IIb/IIIa inhibitor. Its intraarterial (IA) administration as adjunct therapy during mechanical thrombectomy (MT) lacks substantial supportive evidence. Objective: To identify any correlation between IA eptifibatide (135
Abdallah O Amireh, S. Sahito, Zamir Singh, Erica Wan, Ibrahim Abualnadi, Thomas Snyder, S. Scarpiello, Arifa Ghori, Brigitte Percival, Spozhmy Panezai, H. Zacharatos   +10 more
semanticscholar   +1 more source

Abstract WP25: Eptifibatide in Acute Ischemic Strokes Without Large Vessel Occlusions

Stroke
Background: Platelet glycoprotein IIb/IIIa inhibitors are currently being researched for patients with acute ischemic stroke (AIS), however there is no consensus on which inhibitor or dose is both safe and effective.
Subutay B. Bozkurt, Yong-Bum Song, Joshua Haimi, S. Sahito, Muhammad Nabeel Akbar, Paul Fanous, Ibrahim Abualnadi, Abdallah O Amireh, Michael Gates, Marriam Malik, Mariah Siddiqui, Nicholas Briski, sarah Abdelmessih, Yasemin Akinci, Kiapour Nazanin, Hubashia Khan, Nancy E Gadallah, N. Tabibzadeh, Sara Strauss, Arifa Ghori, S. Scarpiello, Thomas Snyder   +21 more
semanticscholar   +1 more source

Acute Profound Thrombocytopenia Associated with Eptifibatide Therapy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
An 80‐year‐old woman and a 79‐year‐old man underwent urgent percutaneous coronary intervention and received adjunctive eptifibatide. Platelet counts in both patients fell to below 20 times 103/mm3 within 4 hours of eptifibatide administration. Reports in the medical literature reinforce the importance of recognizing that eptifibatide can cause acute ...
Cynthia A. Jackevicius, Cynthia A. Jackevicius, Cynthia A. Jackevicius, Peter H. Seidelin, Jeff Nagge, John R. Ross, Vladimir Dzavik, Vladimir Dzavik   +7 more
openaire   +3 more sources

Eptifibatide-Induced Thrombocytopenia and Subsequent Thrombosis

Journal of Pharmacy Technology, 2012
Objective: To report a case of thrombocytopenia and thrombosis associated with the administration of eptifibatide. Case Summary: We describe the case of a 63-year-old male who developed thrombocytopenia and thrombosis associated with eptifibatide administration. Eptifibatide (2 μg/kg/min, following a 180-μg/kg bolus) was administered on hospital day 5,
Hani Kador, Christopher Giuliano, Marjorie Mooney, Stephanie B. Edwin   +3 more
openaire   +2 more sources